Icra sees pharma industry growth tapering to 7-10% over FY18-FY20

The Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report
Source: Livemint.com (http://www.livemint.com/rss/industry)